Skip to main content
SpringerLink
Log in

Rethinking the burden of latent tuberculosis to reprioritize research

  • Comment
  • Published:

From Nature Microbiology

View current issue Submit your manuscript

Analyses refuting the dogma that a quarter of the world’s population is latently infected with Mycobacterium tuberculosis emphasize the need for a redirection of research priorities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Models of TB pathogenesis and disease progression.

References

  1. Behr, M. A., Edelstein, P. H. & Ramakrishnan, L. Br. Med. J. 362, k2738 (2018).

    Article  Google Scholar 

  2. Global Tuberculosis Report 2021 (WHO, 2021); https://go.nature.com/3re4n6j

  3. Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis M72 Vaccine Candidate That Could Be the First in 100 Years if Proven Effective (Bill & Melinda Gates Foundation, 2023); https://go.nature.com/3VVlv8L

  4. Nat. Microbiol. 8, 1601–1602 (2023).

  5. Tozer, L. Nature https://doi.org/10.1038/d41586-023-02171-x (2023).

  6. Behr, M. A., Edelstein, P. H. & Ramakrishnan, L. Br. Med. J. 367, l5770 (2019).

    Article  Google Scholar 

  7. Emery, J. C. et al. Proc. R. Soc. B 288, 20201635 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Global Tuberculosis Report 2023 (WHO, 2023); https://go.nature.com/3PW21Nk

  9. Divangahi, M., Khan, N. & Kaufmann, E. Front. Immunol. 9, 2976 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Roy Chowdhury, R. et al. Nature 560, 644–648 (2018).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

M.A.B. is supported by a Tier 1 Canada Research Chair from the Canadian Institutes for Health Research. L.R. is supported by a Principal Research Fellowship from the Wellcome Trust and a Research Project Grant (RO1) from the National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Medicine, McGill University, McGill International TB Centre, Montreal, Quebec, Canada

    Marcel A. Behr

  2. Department of Medicine, University of Cambridge, Cambridge, UK

    Paul H. Edelstein & Lalita Ramakrishnan

  3. MRC Laboratory of Molecular Biology, Cambridge, UK

    Paul H. Edelstein & Lalita Ramakrishnan

Authors
  1. Marcel A. Behr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul H. Edelstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lalita Ramakrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lalita Ramakrishnan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Microbiology thanks Brian Robertson and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Behr, M.A., Edelstein, P.H. & Ramakrishnan, L. Rethinking the burden of latent tuberculosis to reprioritize research. Nat Microbiol 9, 1157–1158 (2024). https://doi.org/10.1038/s41564-024-01683-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41564-024-01683-0

  • Springer Nature Limited

Search

Navigation